Tumeh and colleagues (29) analyzed the relationship between TILs and response to pembrolizumab in patients with melanoma; the results showed higher CD8+ T cell densities at the invasive margin and within the tumor parenchyma in responding patients than in patients with disease progression. This evidence concerns the gene CD8A and melanoma.